# EDGAR Filing Document

**Accession Number:** 0001865494
**File Stem:** 0000000000-23-001322
**Filing Date:** 2023-2
**Character Count:** 3219
**Document Hash:** 4df2828859e054b6534b9dde4da1a6dd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-001322.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0000000000-23-001322

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230208

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IO Biotech, Inc.
- **CENTRAL INDEX KEY:** 0001865494
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 870909276
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** OLE MAALOES VEH 3
- **CITY:** COPENHAGEN
- **STATE:** G7
- **ZIP:** 2200
- **BUSINESS PHONE:** 4570702980

**MAIL ADDRESS:**
- **STREET 1:** OLE MAALOES VEH 3
- **CITY:** COPENHAGEN
- **STATE:** G7
- **ZIP:** 2200

## Text-Extract

```

United States securities and exchange commission logo

                          February 8, 2023

       Mai-Britt Zocca, Ph.D.
       President and Chief Executive Officer
       IO Biotech, Inc.
       Ole Maal  es Vej 3
       DK-2200 Copenhagen N
       Denmark

                                                        Re: IO Biotech, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed February 3,
2023
                                                            File No. 333-269569

       Dear Mai-Britt Zocca:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Tyler
Howes at 202-551-3370 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Frank Rahmani, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

February 8, 2023

Mai-Britt Zocca, Ph.D.
President and Chief Executive Officer
IO Biotech, Inc.
Ole Maaløes Vej 3
DK-2200 Copenhagen N
Denmark

**Re: IO Biotech, Inc.**
**Registration Statement on Form S-3**
**Filed February 3, 2023**
**File No. 333-269569**

Dear Mai-Britt Zocca:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Tyler Howes at 202-551-3370 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Frank Rahmani, Esq.